GSK and Vir Biotechnology Announce Continuing Progress of the COMET Clinical Development Programme for Sotrovimab

Analysis of final Day 29 data from COMET-ICE confirms sotrovimab significantly reduces hospitalisation and risk of death in adults with mild-to-moderate COVID-19 who are at high risk of progression to severe disease U.S. National Institutes of...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials